Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 76

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis

Jin, Tao, Mohammad, Majd, Pullerits, Rille, Ali, Abukar · 2021 · Pathogens

Abstract

Staphylococcus aureus (S. aureus) infections are a major healthcare challenge and new treatment alternatives are needed. S. aureus septic arthritis, a debilitating joint disease, causes permanent joint dysfunction in almost 50% of the patients. S. aureus bacteremia is associated with higher mortalities than bacteremia caused by most other microbes and can develop to severe sepsis and death. The key to new therapies is understanding the interplay between bacterial virulence factors and host immune response, which decides the disease outcome. S. aureus produces numerous virulence factors that facilitate bacterial dissemination, invasion into joint cavity, and cause septic arthritis. Monocytes, activated by several components of S. aureus such as lipoproteins, are responsible for bone destructions. In S. aureus sepsis, cytokine storm induced by S. aureus components leads to the hyperinflammatory status, DIC, multiple organ failure, and later death. The immune suppressive therapies at the very early time point might be protective. However, the timing of treatment is crucial, as late treatment may aggravate the immune paralysis and lead to uncontrolled infection and death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pathogens10020158

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 169

  1. Bien, 2011, Characterization of Virulence Factors of Staphylococcus aureus: Novel Function of Known Virulence Factors That Are Implicated in Activation of Airway Epithelial Proinflammatory Response, J. Pathog., 2011, 601905
  2. Ali, A. (2016). Biologics in Staphylococcus Aureus Arthritis. [Ph.D. Thesis, University of Gothenburg].
  3. Nanra, 2013, Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus, Hum. Vaccin. Immunother., 9, 480, 10.4161/hv.23223 · doi:10.4161/hv.23223
  4. Nilsson, 1997, The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis, Infect. Immun., 65, 4216, 10.1128/iai.65.10.4216-4221.1997 · DOI
  5. Watts, 2005, Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence, Infect. Immun., 73, 3502, 10.1128/IAI.73.6.3502-3511.2005 · doi:10.1128/iai.73.6.3502-3511.2005
  6. Sharif, 2009, Staphylococcus aureus peptidoglycan tertiary structure from carbon-13 spin diffusion, J. Am. Chem. Soc., 131, 7023, 10.1021/ja808971c · DOI
  7. Vollmer, 2008, Peptidoglycan structure and architecture, FEMS Microbiol. Rev., 32, 149, 10.1111/j.1574-6976.2007.00094.x · DOI · Paper page
  8. Willey, J.M., Sherwood, L., and Woolverton, C.J. (2014). Prescott’s Microbiology, McGraw-Hill. [9th ed.].
  9. Grundling, 2006, Cross-linked peptidoglycan mediates lysostaphin binding to the cell wall envelope of Staphylococcus aureus, J. Bacteriol., 188, 2463, 10.1128/JB.188.7.2463-2472.2006 · DOI · Paper page
  10. Kashyap, 2011, Peptidoglycan recognition proteins kill bacteria by activating protein-sensing two-component systems, Nat. Med., 17, 676, 10.1038/nm.2357 · DOI · Paper page
  11. Liu, 2001, Staphylococcal peptidoglycans induce arthritis, Arthritis Res. Ther., 3, 375, 10.1186/ar330 · DOI
  12. Dusad, 2013, Organic dust, lipopolysaccharide, and peptidoglycan inhalant exposures result in bone loss/disease, Am. J. Respir. Cell Mol. Biol., 49, 829, 10.1165/rcmb.2013-0178OC · DOI
  13. Mohammad, M., Nguyen, M.T., Engdahl, C., Na, M., Jarneborn, A., Hu, Z., Karlsson, A., Pullerits, R., Ali, A., and Gotz, F. (2019). The YIN and YANG of lipoproteins in developing and preventing infectious arthritis by Staphylococcus aureus. PLoS Pathog., 15. · DOI
  14. Bera, 2005, Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O-acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus, Mol. Microbiol., 55, 778, 10.1111/j.1365-2958.2004.04446.x · DOI · Paper page
  15. Sychantha, D., Jones, C.S., Little, D.J., Moynihan, P.J., Robinson, H., Galley, N.F., Roper, D.I., Dowson, C.G., Howell, P.L., and Clarke, A.J. (2017). In vitro characterization of the antivirulence target of Gram-positive pathogens, peptidoglycan O-acetyltransferase A (OatA). PLoS Pathog., 13. · DOI
  16. Baranwal, 2017, Impact of cell wall peptidoglycan O-acetylation on the pathogenesis of Staphylococcus aureus in septic arthritis, Int. J. Med. Microbiol., 307, 388, 10.1016/j.ijmm.2017.08.002 · DOI
  17. Reichmann, 2011, Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes, FEMS Microbiol. Lett., 319, 97, 10.1111/j.1574-6968.2011.02260.x · DOI · Paper page
  18. Brown, 2013, Wall teichoic acids of gram-positive bacteria, Annu. Rev. Microbiol., 67, 313, 10.1146/annurev-micro-092412-155620 · DOI · Paper page
  19. Morath, 2001, Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus, J. Exp. Med., 193, 393, 10.1084/jem.193.3.393 · DOI · Paper page
  20. Morath, 2002, Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release, J. Exp. Med., 195, 1635, 10.1084/jem.20020322 · DOI · Paper page
  21. Nguyen, 2016, Lipoproteins of Gram-Positive Bacteria: Key Players in the Immune Response and Virulence, Microbiol. Mol. Biol. Rev., 80, 891, 10.1128/MMBR.00028-16 · DOI · Paper page
  22. Sheldon, 2012, The iron-regulated staphylococcal lipoproteins, Front. Cell. Infect. Microbiol., 2, 41, 10.3389/fcimb.2012.00041 · DOI
  23. Nguyen, 2017, Lipid moieties on lipoproteins of commensal and non-commensal staphylococci induce differential immune responses, Nat. Commun., 8, 2246, 10.1038/s41467-017-02234-4 · DOI
  24. Mohammad, 2020, The role of Staphylococcus aureus lipoproteins in hematogenous septic arthritis, Sci. Rep., 10, 7936, 10.1038/s41598-020-64879-4 · DOI
  25. Schmaler, 2009, Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-dependent growth in vivo, J. Immunol., 182, 7110, 10.4049/jimmunol.0804292 · DOI
  26. Nguyen, M.T., Kraft, B., Yu, W., Demircioglu, D.D., Hertlein, T., Burian, M., Schmaler, M., Boller, K., Bekeredjian-Ding, I., and Ohlsen, K. (2015). The νSaα Specific Lipoprotein Like Cluster (lpl) of S. aureus USA300 Contributes to Immune Stimulation and Invasion in Human Cells. PLoS Pathog., 11. · doi:10.1371/journal.ppat.1005189
  27. Foster, 2014, Adhesion, invasion and evasion: The many functions of the surface proteins of Staphylococcus aureus, Nat. Rev. Microbiol., 12, 49, 10.1038/nrmicro3161 · DOI · Paper page
  28. Hair, 2010, Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis, Infect. Immun., 78, 1717, 10.1128/IAI.01065-09 · DOI
  29. Josefsson, 2001, Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant, J. Infect. Dis., 184, 1572, 10.1086/324430 · DOI · Paper page
  30. Kobayashi, 2013, Staphylococcus aureus protein A promotes immune suppression, MBio, 4, e00764-13, 10.1128/mBio.00764-13 · DOI
  31. Palmqvist, 2002, Protein A is a virulence factor in Staphylococcus aureus arthritis and septic death, Microb. Pathog., 33, 239, 10.1006/mpat.2002.0533 · DOI · Paper page
  32. Palmqvist, 2005, Fibronectin-binding proteins and fibrinogen-binding clumping factors play distinct roles in staphylococcal arthritis and systemic inflammation, J. Infect. Dis., 191, 791, 10.1086/427663 · doi:10.1086/427663
  33. Switalski, 1993, A collagen receptor on Staphylococcus aureus strains isolated from patients with septic arthritis mediates adhesion to cartilage, Mol. Microbiol., 7, 99, 10.1111/j.1365-2958.1993.tb01101.x · DOI · Paper page
  34. Patti, 1994, The Staphylococcus aureus collagen adhesin is a virulence determinant in experimental septic arthritis, Infect. Immun., 62, 152, 10.1128/iai.62.1.152-161.1994 · DOI · Paper page
  35. Vanassche, 2011, Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence, J. Thromb. Haemost., 9, 2436, 10.1111/j.1538-7836.2011.04529.x · DOI
  36. Na, M., Hu, Z., Mohammad, M., Stroparo, M.D.N., Ali, A., Fei, Y., Jarneborn, A., Verhamme, P., Schneewind, O., and Missiakas, D. (2020). The Expression of von Willebrand Factor-Binding Protein Determines Joint-Invading Capacity of Staphylococcus aureus, a Core Mechanism of Septic Arthritis. mBio, 11. · doi:10.1128/mbio.02472-20
  37. Hammel, 2007, The Staphylococcus aureus extracellular adherence protein (Eap) adopts an elongated but structured conformation in solution, Protein Sci., 16, 2605, 10.1110/ps.073170807 · DOI
  38. Zecconi, 2013, Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases, Immunol. Lett., 150, 12, 10.1016/j.imlet.2013.01.004 · DOI · Paper page
  39. Kwiecinski, 2013, Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity, J. Infect. Dis., 208, 990, 10.1093/infdis/jit288 · DOI
  40. Xu, 2012, Staphylococcal superantigens in colonization and disease, Front. Cell. Infect. Microbiol., 2, 52, 10.3389/fcimb.2012.00052 · DOI · Paper page
  41. McCormick, 2003, Functional analysis of the TCR binding domain of toxic shock syndrome toxin-1 predicts further diversity in MHC class II/superantigen/TCR ternary complexes, J. Immunol., 171, 1385, 10.4049/jimmunol.171.3.1385 · doi:10.4049/jimmunol.171.3.1385
  42. Abdelnour, 1994, Clonal expansion of T lymphocytes causes arthritis and mortality in mice infected with toxic shock syndrome toxin-1-producing staphylococci, Eur. J. Immunol., 24, 1161, 10.1002/eji.1830240523 · DOI
  43. Dinges, 2000, Exotoxins of Staphylococcus aureus, Clin. Microbiol. Rev., 13, 16, 10.1128/CMR.13.1.16 · DOI · Paper page
  44. Omoe, 2013, Emetic potentials of newly identified staphylococcal enterotoxin-like toxins, Infect. Immun., 81, 3627, 10.1128/IAI.00550-13 · doi:10.1128/iai.00550-13
  45. Nilsson, 1999, Alpha-toxin and gamma-toxin jointly promote Staphylococcus aureus virulence in murine septic arthritis, Infect. Immun., 67, 1045, 10.1128/IAI.67.3.1045-1049.1999 · DOI
  46. Cheung, 2014, Phenol-soluble modulins--critical determinants of staphylococcal virulence, FEMS Microbiol. Rev., 38, 698, 10.1111/1574-6976.12057 · DOI · Paper page
  47. Periasamy, 2012, How Staphylococcus aureus biofilms develop their characteristic structure, Proc. Natl. Acad. Sci. USA, 109, 1281, 10.1073/pnas.1115006109 · DOI · Paper page
  48. Peschel, 2013, Phenol-soluble modulins and staphylococcal infection, Nat. Rev. Microbiol., 11, 667, 10.1038/nrmicro3110 · DOI · Paper page
  49. Rasigade, J.P., Trouillet-Assant, S., Ferry, T., Diep, B.A., Sapin, A., Lhoste, Y., Ranfaing, J., Badiou, C., Benito, Y., and Bes, M. (2013). PSMs of hypervirulent Staphylococcus aureus act as intracellular toxins that kill infected osteoblasts. PLoS ONE, 8. · DOI
  50. Fournier, 2005, Recognition of Staphylococcus aureus by the innate immune system, Clin. Microbiol. Rev., 18, 521, 10.1128/CMR.18.3.521-540.2005 · DOI · Paper page
  51. Deng, 1999, Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis, Nat. Med., 5, 702, 10.1038/9554 · DOI · Paper page
  52. Sparwasser, 1997, Bacterial DNA causes septic shock, Nature, 386, 336, 10.1038/386336a0 · DOI · Paper page
  53. Joh, 1999, Role of fibronectin-binding MSCRAMMs in bacterial adherence and entry into mammalian cells, Matrix Biol., 18, 211, 10.1016/S0945-053X(99)00025-6 · DOI · Paper page
  54. An, Y.H., and Friedman, R.J. (2000). Handbook of Bacterial Adhesion Principles, Methods, and Applications, Humana Press.
  55. Chavakis, 2005, Staphylococcus aureus interactions with the endothelium: The role of bacterial “secretable expanded repertoire adhesive molecules” (SERAM) in disturbing host defense systems, Thromb. Haemost., 94, 278, 10.1160/TH05-05-0306 · DOI · Paper page
  56. Claes, 2014, Adhesion of Staphylococcus aureus to the vessel wall under flow is mediated by von Willebrand factor-binding protein, Blood, 124, 1669, 10.1182/blood-2014-02-558890 · doi:10.1182/blood-2014-02-558890
  57. Claes, 2017, Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall, J. Thromb. Haemost., 15, 1009, 10.1111/jth.13653 · DOI
  58. Bardoel, 2012, Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3, J. Mol. Med. (Berl.), 90, 1109, 10.1007/s00109-012-0926-8 · DOI
  59. Ibberson, 2014, Staphylococcus aureus hyaluronidase is a CodY-regulated virulence factor, Infect. Immun., 82, 4253, 10.1128/IAI.01710-14 · DOI
  60. Kwiecinski, 2016, Staphylokinase Control of Staphylococcus aureus Biofilm Formation and Detachment Through Host Plasminogen Activation, J. Infect. Dis., 213, 139, 10.1093/infdis/jiv360 · DOI
  61. Fraser, J.D. (2011). Clarifying the mechanism of superantigen toxicity. PLoS Biol., 9. · DOI
  62. McCormick, 2001, Toxic shock syndrome and bacterial superantigens: An update, Annu. Rev. Microbiol., 55, 77, 10.1146/annurev.micro.55.1.77 · DOI · Paper page
  63. Marrack, 1990, The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells, J. Exp. Med., 171, 455, 10.1084/jem.171.2.455 · DOI · Paper page
  64. Kaempfer, 2013, CD28: Direct and critical receptor for superantigen toxins, Toxins (Basel), 5, 1531, 10.3390/toxins5091531 · DOI
  65. Gouaux, 1998, alpha-Hemolysin from Staphylococcus aureus: An archetype of beta-barrel, channel-forming toxins, J. Struct. Biol., 121, 110, 10.1006/jsbi.1998.3959 · DOI · Paper page
  66. Deng, 2001, Intracisternally localized bacterial DNA containing CpG motifs induces meningitis, J. Immunol., 167, 4616, 10.4049/jimmunol.167.8.4616 · DOI
  67. Ali, 2015, Antibiotic-killed Staphylococcus aureus induces destructive arthritis in mice, Arthritis Rheumatol., 67, 107, 10.1002/art.38902 · DOI
  68. Verdrengh, 1997, Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus, Infect. Immun., 65, 2517, 10.1128/iai.65.7.2517-2521.1997 · DOI · Paper page
  69. Verdrengh, 2000, Role of macrophages in Staphylococcus aureus-induced arthritis and sepsis, Arthritis Rheum., 43, 2276, 10.1002/1529-0131(200010)43:10<2276::AID-ANR15>3.0.CO;2-C · doi:10.1002/1529-0131(200010)43:10<2276::aid-anr15>3.0.co;2-c
  70. Nilsson, 1999, Protective role of NK1.1+ cells in experimental Staphylococcus aureus arthritis, Clin. Exp. Immunol., 117, 63, 10.1046/j.1365-2249.1999.00922.x · DOI
  71. Krishack, P.A., Louviere, T.J., Decker, T.S., Kuzel, T.G., Greenberg, J.A., Camacho, D.F., Hrusch, C.L., Sperling, A.I., and Verhoef, P.A. (2019). Protection against Staphylococcus aureus bacteremia-induced mortality depends on ILC2s and eosinophils. JCI Insight, 4. · DOI
  72. Abdelnour, 1994, Role of T lymphocytes in experimental Staphylococcus aureus arthritis, Scand. J. Immunol., 39, 403, 10.1111/j.1365-3083.1994.tb03392.x · doi:10.1111/j.1365-3083.1994.tb03392.x
  73. Bergmann, B., Fei, Y., Jirholt, P., Hu, Z., Bergquist, M., Ali, A., Lindholm, C., Ekwall, O., Churlaud, G., and Klatzmann, D. (2020). Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice. BMC Infect. Dis., 20. · DOI
  74. Gjertsson, 2000, Are B lymphocytes of importance in severe Staphylococcus aureus infections?, Infect. Immun., 68, 2431, 10.1128/IAI.68.5.2431-2434.2000 · DOI
  75. Wuescher, 2015, A novel conditional platelet depletion mouse model reveals the importance of platelets in protection against Staphylococcus aureus bacteremia, J. Thromb. Haemost., 13, 303, 10.1111/jth.12795 · DOI
  76. Piliponsky, 2019, Basophil-derived tumor necrosis factor can enhance survival in a sepsis model in mice, Nat. Immunol., 20, 129, 10.1038/s41590-018-0288-7 · DOI
  77. Akira, 2006, Pathogen recognition and innate immunity, Cell, 124, 783, 10.1016/j.cell.2006.02.015 · DOI · Paper page
  78. Abbas, A.K., and Lichtman, A.H. (2009). Basic Immunology: Functions and Disorders of the Immune System, Saunders/Elsevier. [3rd ed.].
  79. Molne, 2000, Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus, Infect. Immun., 68, 6162, 10.1128/IAI.68.11.6162-6167.2000 · DOI
  80. Mills, 2015, Anatomy of a discovery: m1 and m2 macrophages, Front. Immunol., 6, 212, 10.3389/fimmu.2015.00212 · DOI · Paper page
  81. Rath, 2014, Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages, Front. Immunol., 5, 532, 10.3389/fimmu.2014.00532 · DOI · Paper page
  82. Mosser, 2008, Exploring the full spectrum of macrophage activation, Nat. Rev. Immunol., 8, 958, 10.1038/nri2448 · DOI · Paper page
  83. Makita, 2015, IL-10 enhances the phenotype of M2 macrophages induced by IL-4 and confers the ability to increase eosinophil migration, Int. Immunol., 27, 131, 10.1093/intimm/dxu090 · DOI · Paper page
  84. Tanaka, 2005, Osteoblasts and osteoclasts in bone remodeling and inflammation, Curr. Drug Targets Inflamm. Allergy, 4, 325, 10.2174/1568010054022015 · DOI · Paper page
  85. Ogata, 1999, A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2, J. Immunol., 162, 2754, 10.4049/jimmunol.162.5.2754 · DOI
  86. Djaafar, 2010, Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice, Arthritis Rheum., 62, 3300, 10.1002/art.27645 · DOI
  87. Henningsson, 2012, Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis, J. Infect. Dis., 206, 687, 10.1093/infdis/jis295 · DOI
  88. Verdrengh, 2010, RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis, Bone, 46, 752, 10.1016/j.bone.2009.10.028 · DOI
  89. Deng, 2000, The major role of macrophages and their product tumor necrosis factor alpha in the induction of arthritis triggered by bacterial DNA containing CpG motifs, Arthritis Rheum., 43, 2283, 10.1002/1529-0131(200010)43:10<2283::AID-ANR16>3.0.CO;2-9 · doi:10.1002/1529-0131(200010)43:10<2283::aid-anr16>3.0.co;2-9
  90. Small, 2008, NK cells play a critical protective role in host defense against acute extracellular Staphylococcus aureus bacterial infection in the lung, J. Immunol., 180, 5558, 10.4049/jimmunol.180.8.5558 · DOI
  91. Laarman, 2011, Staphylococcus aureus metalloprotease aureolysin cleaves complement C3 to mediate immune evasion, J. Immunol., 186, 6445, 10.4049/jimmunol.1002948 · DOI · Paper page
  92. Laarman, 2010, Complement inhibition by gram-positive pathogens: Molecular mechanisms and therapeutic implications, J. Mol. Med. (Berl.), 88, 115, 10.1007/s00109-009-0572-y · DOI
  93. Sakiniene, 1999, Complement depletion aggravates Staphylococcus aureus septicaemia and septic arthritis, Clin. Exp. Immunol., 115, 95, 10.1046/j.1365-2249.1999.00771.x · DOI
  94. Na, M., Jarneborn, A., Ali, A., Welin, A., Magnusson, M., Stokowska, A., Pekna, M., and Jin, T. (2016). Deficiency of the complement component 3 but not factor B aggravates Staphylococcus aureus septic arthritis in mice. Infect. Immun. · DOI
  95. Andersen, 2006, Cytotoxic T cells, J. Investig. Dermatol., 126, 32, 10.1038/sj.jid.5700001 · DOI · Paper page
  96. Sakaguchi, 2008, Regulatory T cells and immune tolerance, Cell, 133, 775, 10.1016/j.cell.2008.05.009 · DOI · Paper page
  97. Tesmer, 2008, Th17 cells in human disease, Immunol. Rev., 223, 87, 10.1111/j.1600-065X.2008.00628.x · DOI · Paper page
  98. Kidd, 2003, Th1/Th2 balance: The hypothesis, its limitations, and implications for health and disease, Altern. Med. Rev., 8, 223
  99. Romagnani, 1999, Th1/Th2 cells, Inflamm. Bowel Dis., 5, 285, 10.1097/00054725-199911000-00009 · DOI · Paper page
  100. Oosterwegel, 1999, The role of CTLA-4 in regulating Th2 differentiation, J. Immunol., 163, 2634, 10.4049/jimmunol.163.5.2634 · DOI
  101. Ali, 2015, CTLA4 Immunoglobulin but Not Anti-Tumor Necrosis Factor Therapy Promotes Staphylococcal Septic Arthritis in Mice, J. Infect. Dis., 212, 1308, 10.1093/infdis/jiv212 · DOI
  102. Parker, 2015, CD4+ T cells promote the pathogenesis of Staphylococcus aureus pneumonia, J. Infect. Dis., 211, 835, 10.1093/infdis/jiu525 · DOI
  103. Jin, 2019, A novel mouse model for septic arthritis induced by Pseudomonas aeruginosa, Sci. Rep., 9, 16868, 10.1038/s41598-019-53434-5 · DOI
  104. Henningsson, 2010, Interleukin-17A during local and systemic Staphylococcus aureus-induced arthritis in mice, Infect. Immun., 78, 3783, 10.1128/IAI.00385-10 · DOI
  105. Kwiecinski, 2013, Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway, Infect. Immun., 81, 1114, 10.1128/IAI.01334-12 · DOI
  106. Sonnenberg, 2019, Functional interactions between innate lymphoid cells and adaptive immunity, Nat. Rev. Immunol., 19, 599, 10.1038/s41577-019-0194-8 · DOI · Paper page
  107. Ali, 2017, Platelets Mediate Host Defense against Staphylococcus aureus through Direct Bactericidal Activity and by Enhancing Macrophage Activities, J. Immunol., 198, 344, 10.4049/jimmunol.1601178 · DOI
  108. Hultgren, 1998, TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus, J. Immunol., 161, 5937, 10.4049/jimmunol.161.11.5937 · DOI
  109. Hultgren, 2002, Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection, J. Immunol., 168, 5207, 10.4049/jimmunol.168.10.5207 · DOI
  110. Lenski, 2014, The significance of interleukin-6 and lactate in the synovial fluid for diagnosing native septic arthritis, Acta Orthop. Belg., 80, 18
  111. Hultgren, 2001, Role of IL-12 in Staphylococcus aureus-triggered arthritis and sepsis, Arthritis Res., 3, 41, 10.1186/ar138 · DOI
  112. Hultgren, 1998, Staphylococcus aureus-induced septic arthritis and septic death is decreased in IL-4-deficient mice: Role of IL-4 as promoter for bacterial growth, J. Immunol., 160, 5082, 10.4049/jimmunol.160.10.5082 · DOI
  113. Hultgren, 1999, Outcome of Staphylococcus aureus-triggered sepsis and arthritis in IL-4-deficient mice depends on the genetic background of the host, Eur. J. Immunol., 29, 2400, 10.1002/(SICI)1521-4141(199908)29:08<2400::AID-IMMU2400>3.0.CO;2-E · doi:10.1002/(sici)1521-4141(199908)29:08<2400::aid-immu2400>3.0.co;2-e
  114. Gjertsson, 2002, Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance, Clin. Exp. Immunol., 130, 409, 10.1046/j.1365-2249.2002.01999.x · doi:10.1046/j.1365-2249.2002.01999.x
  115. Zhao, 1998, The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis, Immunology, 93, 80, 10.1046/j.1365-2567.1998.00407.x · DOI
  116. Jarneborn, 2020, Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice, Sci. Rep., 10, 10891, 10.1038/s41598-020-67928-0 · DOI
  117. Davis, 2011, The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus, J. Interferon Cytokine Res., 31, 781, 10.1089/jir.2011.0047 · DOI
  118. Osiri, 1998, IL-1beta, IL-6 and TNF-alpha in synovial fluid of patients with non-gonococcal septic arthritis, Asian Pac. J. Allergy Immunol., 16, 155
  119. Na, M., Wang, W., Fei, Y., Josefsson, E., Ali, A., and Jin, T. (2017). Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS ONE, 12. · DOI
  120. Jacques, 2006, The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation, Vitam. Horm., 74, 371, 10.1016/S0083-6729(06)74016-X · DOI · Paper page
  121. Zhao, 1995, Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis, J. Immunol., 155, 5736, 10.4049/jimmunol.155.12.5736 · DOI
  122. 1998, Cytokines induce the development of functionally heterogeneous T helper cell subsets, Immunity, 8, 275, 10.1016/S1074-7613(00)80533-6 · DOI · Paper page
  123. Ivanov, 2009, Interleukin-17 as a drug target in human disease, Trends Pharmacol. Sci., 30, 95, 10.1016/j.tips.2008.11.004 · DOI
  124. Sharff, 2013, Clinical management of septic arthritis, Curr. Rheumatol. Rep., 15, 332, 10.1007/s11926-013-0332-4 · DOI
  125. Tarkowski, 2006, Infection and musculoskeletal conditions: Infectious arthritis, Best Pract. Res. Clin. Rheumatol., 20, 1029, 10.1016/j.berh.2006.08.001 · DOI
  126. Goldenberg, 1998, Septic arthritis, Lancet, 351, 197, 10.1016/S0140-6736(97)09522-6 · DOI · Paper page
  127. Balsa, 2011, Septic arthritis, Best Pract. Res. Clin. Rheumatol., 25, 407, 10.1016/j.berh.2011.02.001 · DOI · Paper page
  128. Mathews, 2010, Bacterial septic arthritis in adults, Lancet, 375, 846, 10.1016/S0140-6736(09)61595-6 · DOI · Paper page
  129. Morgan, 1996, An 18 year clinical review of septic arthritis from tropical Australia, Epidemiol. Infect., 117, 423, 10.1017/S0950268800059070 · DOI · Paper page
  130. Fowler, 1998, Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: Experience with 244 patients, Clin. Infect. Dis., 27, 478, 10.1086/514686 · DOI · Paper page
  131. Marr, 1998, Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients, Kidney Int., 54, 1684, 10.1046/j.1523-1755.1998.00134.x · DOI · Paper page
  132. Naber, 2009, Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies, Clin. Infect. Dis., 48, S231, 10.1086/598189 · DOI · Paper page
  133. Holland, 2014, Clinical management of Staphylococcus aureus bacteremia: A review, JAMA, 312, 1330, 10.1001/jama.2014.9743 · DOI · Paper page
  134. Martin, 2012, Sepsis, severe sepsis and septic shock: Changes in incidence, pathogens and outcomes, Expert. Rev. Anti Infect. Ther., 10, 701, 10.1586/eri.12.50 · DOI · Paper page
  135. Kuiper, 2003, Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock, Clin. Microbiol. Rev., 16, 379, 10.1128/CMR.16.3.379-414.2003 · DOI · Paper page
  136. Huttunen, 2011, New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis, J. Infect., 63, 407, 10.1016/j.jinf.2011.08.004 · DOI
  137. Semeraro, 2010, Sepsis-associated disseminated intravascular coagulation and thromboembolic disease, Mediterr. J. Hematol. Infect. Dis., 2, e2010024, 10.4084/mjhid.2010.024 · DOI · Paper page
  138. Romling, 2012, Biofilm infections, their resilience to therapy and innovative treatment strategies, J. Intern. Med., 272, 541, 10.1111/joim.12004 · DOI · Paper page
  139. Stoodley, 2008, Direct demonstration of viable Staphylococcus aureus biofilms in an infected total joInt. arthroplasty. A case report, J. Bone Joint Surg. Am., 90, 1751, 10.2106/JBJS.G.00838 · DOI · Paper page
  140. Dastgheyb, 2015, Effect of biofilms on recalcitrance of staphylococcal joInt. infection to antibiotic treatment, J. Infect. Dis., 211, 641, 10.1093/infdis/jiu514 · DOI · Paper page
  141. Davies, 2003, Understanding biofilm resistance to antibacterial agents, Nat. Rev. Drug Discov., 2, 114, 10.1038/nrd1008 · DOI · Paper page
  142. Kwiecinski, 2015, Biofilm formation by Staphylococcus aureus isolates from skin and soft tissue infections, Curr. Microbiol., 70, 698, 10.1007/s00284-014-0770-x · DOI
  143. Otto, 2013, Staphylococcal infections: Mechanisms of biofilm maturation and detachment as critical determinants of pathogenicity, Annu. Rev. Med., 64, 175, 10.1146/annurev-med-042711-140023 · DOI · Paper page
  144. Kwiecinski, 2015, Tissue Plasminogen Activator Coating on Implant Surfaces Reduces Staphylococcus aureus Biofilm Formation, Appl. Environ. Microbiol., 82, 394, 10.1128/AEM.02803-15 · DOI
  145. Libertucci, 2019, The role of the microbiota in infectious diseases, Nat. Microbiol., 4, 35, 10.1038/s41564-018-0278-4 · DOI · Paper page
  146. Sewankambo, 1997, HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis, Lancet, 350, 546, 10.1016/S0140-6736(97)01063-5 · DOI · Paper page
  147. Hyoju, S.K., Zaborin, A., Keskey, R., Sharma, A., Arnold, W., van den Berg, F., Kim, S.M., Gottel, N., Bethel, C., and Charnot-Katsikas, A. (2019). Mice Fed an Obesogenic Western Diet, Administered Antibiotics, and Subjected to a Sterile Surgical Procedure Develop Lethal Septicemia with Multidrug-Resistant Pathobionts. mBio, 10. · DOI
  148. Wu, 2010, Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells, Immunity, 32, 815, 10.1016/j.immuni.2010.06.001 · DOI · Paper page
  149. Jubair, 2018, Modulation of Inflammatory Arthritis in Mice by Gut Microbiota Through Mucosal Inflammation and Autoantibody Generation, Arthritis Rheumatol., 70, 1220, 10.1002/art.40490 · DOI · Paper page
  150. Breban, 2017, Faecal microbiota study reveals specific dysbiosis in spondyloarthritis, Ann. Rheum. Dis., 76, 1614, 10.1136/annrheumdis-2016-211064 · DOI · Paper page
  151. Ulici, 2018, Osteoarthritis induced by destabilization of the medial meniscus is reduced in germ-free mice, Osteoarthr. Cartil., 26, 1098, 10.1016/j.joca.2018.05.016 · DOI
  152. Henrotin, Y., Patrier, S., Pralus, A., Roche, M., and Nivoliez, A. (2019). Protective Actions of Oral Administration of Bifidobacterium longum CBi0703 in Spontaneous Osteoarthritis in Dunkin Hartley Guinea Pig Model. Cartilage, 1947603519841674. · doi:10.1177/1947603519841674
  153. Rios, 2019, Protective effect of prebiotic and exercise intervention on knee health in a rat model of diet-induced obesity, Sci. Rep., 9, 3893, 10.1038/s41598-019-40601-x · DOI
  154. Kaandorp, 1995, Risk factors for septic arthritis in patients with joint disease. A prospective study, Arthritis Rheum., 38, 1819, 10.1002/art.1780381215 · DOI · Paper page
  155. Walsh, 2010, Bone remodeling in rheumatic disease: A question of balance, Immunol. Rev., 233, 301, 10.1111/j.0105-2896.2009.00857.x · DOI · Paper page
  156. Udagawa, 1990, Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells, Proc. Natl. Acad. Sci. USA, 87, 7260, 10.1073/pnas.87.18.7260 · DOI · Paper page
  157. Fei, 2011, The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice, J. Infect. Dis., 204, 348, 10.1093/infdis/jir266 · DOI
  158. Ali, A., Na, M., Svensson, M.N., Magnusson, M., Welin, A., Schwarze, J.C., Mohammad, M., Josefsson, E., Pullerits, R., and Jin, T. (2015). IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice. PLoS ONE, 10. · DOI
  159. Okusawa, 1988, Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition, J. Clin. Investig., 81, 1162, 10.1172/JCI113431 · DOI · Paper page
  160. Wang, 1999, HMG-1 as a late mediator of endotoxin lethality in mice, Science, 285, 248, 10.1126/science.285.5425.248 · DOI · Paper page
  161. Fisher, 1996, Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group, N. Engl. J. Med., 334, 1697, 10.1056/NEJM199606273342603 · DOI · Paper page
  162. Richter, 2016, Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis, Ann. Rheum. Dis., 75, 1667, 10.1136/annrheumdis-2015-207838 · DOI
  163. Fattahi, 2017, Understanding Immunosuppression after Sepsis, Immunity, 47, 3, 10.1016/j.immuni.2017.07.007 · DOI
  164. Lowy, 1998, Staphylococcus aureus infections, N. Engl. J. Med., 339, 520, 10.1056/NEJM199808203390806 · DOI · Paper page
  165. Miller, 2020, Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms, FEMS Microbiol. Rev., 44, 123, 10.1093/femsre/fuz030 · DOI · Paper page
  166. Smith, 1997, Staphylococcal septic arthritis: Antibiotic and nonsteroidal anti-inflammatory drug treatment in a rabbit model, J. Orthop. Res., 15, 919, 10.1002/jor.1100150619 · doi:10.1002/jor.1100150619
  167. Ferreira, 2018, A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation, Am. J. Hum. Genet., 103, 553, 10.1016/j.ajhg.2018.09.003 · DOI
  168. Sakiniene, 1996, Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis, Arthritis Rheum., 39, 1596, 10.1002/art.1780390921 · DOI
  169. Odio, 2003, Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children, Pediatr. Infect. Dis. J., 22, 883, 10.1097/01.inf.0000091293.32187.7b · DOI

Cited by

See all 76

Metadata

Authors
Jin, T., Mohammad, M., Pullerits, R., & Ali, A.
Venue
Pathogens
Publisher
MDPI AG
Published
2021-02-03
Volume
10
Issue
2
Pages
158
ISSN
2076-0817
Cited by
76
References
18
Language
en
Funders
Vetenskapsrådet (2019-01135)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis. https://app.cochat.ai/papers/10.3390/pathogens10020158
The paper
Jin, T., Mohammad, M., Pullerits, R., & Ali, A. (2021). Bacteria and Host Interplay in Staphylococcus aureus Septic Arthritis and Sepsis. Pathogens. https://doi.org/10.3390/pathogens10020158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.